



Kingdom of Saudi Arabia
Saudi Food & Drug Authority



Descriptive report of Adverse Events (ADEs)

Data in Saudi Arabia, Q3 2025

**DATA CAPTURE SECTION
NATIONAL PHARMACOVIGILANCE CENTER**



General notes:

Data Report: National Pharmacovigilance Centre

- **Source:** Spontaneous Vigilance System, National Pharmacovigilance Centre
- **Scope:** Adverse event reports, these are medical occurrences noted after the use of a medication, but not necessarily imply a direct causal link to the drug.
- **Parameters:**
 1. Drug reports only (vaccine reports excluded)
 2. Data extract from 1 July to 30 September 2025.


Understanding Pharmacovigilance:

The National Pharmacovigilance Centre plays a crucial role in post-market drug safety monitoring. By collecting and analyzing adverse drug event reports, it helps identify potential safety signals and facilitates interventions to protect public health.


Important Notes:

It's vital to understand that reports of adverse events following drug use do not automatically prove the drug caused the event. Careful assessment is needed to establish any potential relationship.


Number of ADEs in the system




Number of reports based on organization type




Reports seriousness




Top 5 reported Drugs (by Generic Name)




Reports count by Gender




Top 5 reported ADEs (by MedDRA Desc)




Contribution in the Database by Administrative Sectors (Hospitals)




Contribution in the Database by Region




**Top 3 reported drugs from
Makkah region**




Reprts Seriousness




**Top 3 reported drugs from
Eastern region**



Reprts Seriousness



**Top 3 reported drugs from Asir
region**



Reprts Seriousness

